Assertio Holdings, Inc. (ASRT)

Market Cap	116.14M +67.1%
Revenue (ttm)	118.71M -5.0%
Net Income	-30.38M
EPS	-4.74
Shares Out	6.45M
PE Ratio	n/a
Forward PE	29.54
Dividend	n/a
Ex-Dividend Date	n/a

Volume	372,588
Open	18.02
Previous Close	18.02
Day's Range	18.02 - 18.10
52-Week Range	8.18 - 20.45
Beta	0.43
Analysts	Hold
Price Target	18.00 (-0.11%)
Earnings Date	May 11, 2026

About ASRT

Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older;...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 5, 1997
• Employees: 53
• Stock Exchange: NASDAQ
• Ticker Symbol: ASRT
• Website: https://www.assertiotx.com

Financial Performance

In 2025, Assertio Holdings's revenue was $118.71 million, a decrease of -5.00% compared to the previous year's $124.96 million. Losses were -$30.38 million, 40.7% more than in 2024.

Analyst Summary

According to 2 analysts, the average rating for ASRT stock is "Hold." The 12-month stock price target is $18.0, which is a decrease of -0.11% from the latest price.

Price Target

$18.0

(-0.11% downside)

Analyst Consensus: Hold